Advisory - One lot of pms-PROGESTERONE 100 mg capsules recalled because it may pose serious risks to individuals with severe peanut allergies
OTTAWA, ON, Aug. 24, 2021 /CNW/ -
Summary
Product: pms-PROGESTERONE 100 mg capsules (DIN 02476576) Issue: Pharmascience Inc. is recalling one lot (1318593, expiry 10/2022) of pms-PROGESTERONE 100 mg capsules because the bottles may contain capsules from another manufacturer, Akorn 100 mg progesterone capsules. The Akorn capsules contain peanut oil, which poses serious risks to individuals with severe peanut allergies. Akorn 100 mg progesterone is not authorized for sale in Canada. The pms-PROGESTERONE 100 mg capsules are round and beige with "100" printed in black on the capsule, while the Akorn 100 mg progesterone capsules are round and pink with "AK" printed in black on the capsule.
What to do:
If you have severe peanut allergies, stop using your medication and return it to the pharmacy to get a replacement bottle.
If you do NOT have peanut allergies and you find any Akorn progesterone capsules (pink marked with "AK"), return your bottle to the pharmacy for disposal of the Akorn progesterone doses and to receive replacement doses of pms-PROGESTERONE.
Issue Pharmascience Inc. is recalling one lot (1318593, expiry 10/2022) of pms-PROGESTERONE 100 mg capsules because the bottles may contain Akorn 100 mg progesterone gelatin capsules in addition to or instead of the intended pms-PROGESTERONE 100 mg gelatin capsules. The Akorn capsules contain peanut oil, an ingredient that is not listed on the label of pms-PROGESTERONE 100 mg capsules. Peanuts may cause life-threatening allergic reactions (anaphylaxis) in individuals with severe peanut allergies.
pms-PROGESTERONE is a prescription hormone drug used as part of hormone replacement therapy for menopause in women.
The pms-PROGESTERONE 100 mg capsules are round and beige with "100" printed in black on the capsule, while the Akorn 100 mg progesterone capsules are round and pink with "AK" printed in black on the capsule.
The Pharmascience and Akorn capsules contain the same dose of the active ingredient, progesterone. Akorn 100 mg progesterone capsule is not authorized for sale in Canada and therefore it has not been reviewed by Health Canada for its safety, efficacy and quality.
Health Canada is monitoring the recall. If additional safety information is identified, Health Canada will take appropriate action and inform Canadians as needed.
Affected products
Company
Product
DIN
Lot
Expiry
Pharmascience Inc.
pms-PROGESTERONE 100 mg capsules
100-capsule bottles
02476576
1318593
10/2022
What you should do
If you have severe peanut allergies, stop using your medication and return it to the pharmacy to get a replacement bottle.
If you do NOT have peanut allergies and if you find any Akorn progesterone capsules (pink marked with "AK"), return your bottle to the pharmacy for disposal of the Akorn progesterone doses and to receive replacement doses of pms-PROGESTERONE.
Consult a health care professional if you have used these products and have health concerns.
Contact Pharmascience Inc. by calling, toll-free, 1-800-340-9735, or by email at [email protected] if you have questions about the recall.
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...